Genetic variants associated with gastrointestinal symptoms in Fabry disease

Gastrointestinal symptoms (GIS) are often among the earliest presenting events in Fabry disease (FD), an X-linked lysosomal disorder caused by the deficiency of α-galactosidase A. Despite recent advances in clinical and molecular characterization of FD, the pathophysiology of the GIS is still poorly understood. To shed light either on differential clinical presentation or on intervariability of GIS in FD, we genotyped 1936 genetic markers across 231 genes that encode for drug-metabolizing enzymes and drug transport proteins in 49 FD patients, using the DMET Plus platform. All nine single nucleotide polymorphisms (SNPs) mapped within four genes showed statistically significant differences in genotype frequencies between FD patients who experienced GIS and patients without GIS: ABCB11 (odd ratio (OR) = 18.07, P = 0,0019; OR = 8.21, P = 0,0083; OR=8.21, P = 0,0083; OR = 8.21, P = 0,0083),SLCO1B1 (OR = 9.23, P = 0,0065; OR = 5.08, P = 0,0289; OR = 8.21, P = 0,0083), NR1I3 (OR = 5.40, P = 0,0191) and ABCC5 (OR = 14.44, P = 0,0060). This is the first study that investigates the relationships between genetic heterogeneity in drug absorption, distribution, metabolism and excretion (ADME) related genes and GIS in FD. Our findings provide a novel genetic variant framework which warrants further investigation for precision medicine in FD.

[1]  K. Köhrer,et al.  Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump. , 2006, Journal of clinical gastroenterology.

[2]  Mario Cannataro,et al.  Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis , 2015, Cancer Chemotherapy and Pharmacology.

[3]  Mario Cannataro,et al.  OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes , 2016, Microarrays.

[4]  E. Riccio,et al.  [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature]. , 2013, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.

[5]  R. Schwartz.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy , 1996 .

[6]  A. Kosters,et al.  Bile acid transporters in health and disease , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  A. Tuttolomondo,et al.  Neurological complications of Anderson-Fabry disease. , 2013, Current pharmaceutical design.

[8]  F. Suchy,et al.  Bile salt excretory pump: biology and pathobiology. , 2006, Journal of pediatric gastroenterology and nutrition.

[9]  P. Dawson,et al.  Bile acid transporters , 2009, Journal of Lipid Research.

[10]  K. Macdermot,et al.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females , 2001, Journal of medical genetics.

[11]  P. Neuvonen,et al.  Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate , 2008, Pharmacogenetics and genomics.

[12]  M. Camilleri.  Bile Acid Diarrhea: Prevalence, Pathogenesis, and Therapy , 2015, Gut and liver.

[13]  Bradley L Urquhart,et al.  Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.

[14]  D. Häussinger,et al.  Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. , 2006, Gastroenterology.

[15]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[16]  S. Feriozzi,et al.  Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson–Fabry disease: testing the effects with the Mainz Severity Score Index , 2008, Clinical genetics.

[17]  Richard J. Thompson,et al.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.

[18]  Mario Cannataro,et al.  Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study , 2011, Cancer biology & therapy.

[19]  S. Sestito,et al.  Anderson-Fabry disease in children. , 2013, Current pharmaceutical design.

[20]  Mario Cannataro,et al.  DMET-Analyzer: automatic analysis of Affymetrix DMET Data , 2012, BMC Bioinformatics.

[21]  Mario Cannataro,et al.  DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine , 2016, Oncotarget.

[22]  Mario Cannataro,et al.  A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling , 2011, British journal of haematology.

[23]  C. Eng,et al.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. , 2003, Kidney international.

[24]  A. Mehta,et al.  Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  A. Tuttolomondo,et al.  Anderson-Fabry disease: a multiorgan disease. , 2013, Current pharmaceutical design.

[26]  P. Meier,et al.  Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury , 2007, Pharmacogenetics and genomics.

[27]  A. Staiano,et al.  Subtypes of irritable bowel syndrome in children: prevalence at diagnosis and at follow-up. , 2014, The Journal of pediatrics.

[28]  D. F. Moore,et al.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.

[29]  Richard J. Thompson,et al.  Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre‐messenger RNA splicing , 2009, Hepatology.

[30]  R. Desnick.  α-Galactosidase A deficiency. Fabry disease , 2001 .

[31]  F. Lammert,et al.  Hepatic Overexpression of Murine Abcb11 Increases Hepatobiliary Lipid Secretion and Reduces Hepatic Steatosis* , 2004, Journal of Biological Chemistry.

[32]  C. Eng,et al.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. , 2001, The New England journal of medicine.

[33]  A. Zinsmeister,et al.  Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  D. Keppler,et al.  The Multidrug Resistance Protein 5 Functions as an ATP-dependent Export Pump for Cyclic Nucleotides* , 2000, The Journal of Biological Chemistry.

[35]  S. Sestito,et al.  Gastrointestinal Symptoms of Patients with Fabry Disease , 2015, Gastroenterology research and practice.

[36]  R. Evers,et al.  Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex , 2014, Drug Metabolism and Disposition.

[37]  F. Pieruzzi,et al.  Intrafamilial phenotypic variability in four families with Anderson‐Fabry disease , 2014, Clinical genetics.

[38]  G. Boccia,et al.  Functional defecation disorders in children: PACCT criteria versus Rome II criteria. , 2007, The Journal of pediatrics.

[39]  M. Trauner,et al.  Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. , 2011, Biochimica et biophysica acta.

[40]  M. Brys,et al.  Small Fiber Dysfunction Predominates in Fabry Neuropathy , 2002, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.